Importer of Controlled Substances Application: Xcelience, 41065-41066 [2020-14623]
Download as PDF
<![CDATA[
41065
Federal Register / Vol. 85, No. 131 / Wednesday, July 8, 2020 / Notices
personnel will sign appropriate
nondisclosure agreements.
Controlled
substance
Authority: These investigations are being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.12 of the
Commission’s rules.
By order of the Commission.
Issued: July 1, 2020.
Lisa Barton,
Secretary to the Commission.
Drug code
Psilocyn ...................
7438
Schedule
I
The institute plans to import the
listed controlled substances for
potential formulation development for
substances to be used in institutesponsored research.
[FR Doc. 2020–14625 Filed 7–7–20; 8:45 am]
BILLING CODE 7020–02–P
[FR Doc. 2020–14624 Filed 7–7–20; 8:45 am]
Drug Enforcement Administration
[Docket No. DEA–680]
ACTION:
Importer of Controlled Substances
Application: Galephar Pharmaceutical
Research, Inc.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 7, 2020. Such persons
may also file a written request for a
hearing on the application on or before
August 7, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on May 21, 2020, Usona
Institute, 2780 Woods Hollow Road,
Room 2412, Fitchburg, Wisconsin
53711–5370, applied to be registered as
an importer of the following basic
class(es) of controlled substances:
jbell on DSKJLSW7X2PROD with NOTICES
DATES:
Controlled
substance
5-Methoxy-N-Ndimethyltryptamine.
Dimethyltryptamine ..
Psilocybin ................
VerDate Sep<11>2014
Drug code
Schedule
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 7, 2020. Such persons
may also file a written request for a
hearing on the application on or before
August 7, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on June 22, 2020, Galephar
Pharmaceutical Research, Inc., 100 Carr
198 Industrial Park, Juncos, Puerto Rico
00777–3873, applied to be registered as
an importer of the following basic
class(es) of a controlled substance:
DATES:
7431
I
Controlled
substance
7435
7437
I
I
Hydromorphone .......
17:17 Jul 07, 2020
Jkt 250001
PO 00000
Frm 00104
Fmt 4703
[Docket No. DEA–681]
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 7, 2020. Such persons
may also file a written request for a
hearing on the application on or before
August 7, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on May 28, 2020,
Xcelience, 4901 West Grace Street,
Tampa, Florida 33607–3805, applied to
be registered as an Importer of the
following basic class(es) of controlled
substances:
DATES:
[Docket No. DEA–679]
Notice of application.
BILLING CODE P
Importer of Controlled Substances
Application: Xcelience
DEPARTMENT OF JUSTICE
Importer of Controlled Substances
Application: Usona Institute
[FR Doc. 2020–14614 Filed 7–7–20; 8:45 am]
Drug Enforcement Administration
BILLING CODE P
Drug Enforcement Administration
William T. McDermott,
Assistant Administrator.
DEPARTMENT OF JUSTICE
William T. McDermott,
Assistant Administrator.
DEPARTMENT OF JUSTICE
The company plans to import the
listed controlled substance in finished
dosage form for analytical purpose only.
Drug code
9150
Sfmt 4703
Schedule
II
Controlled
substance
Psilocybin ................
Amphetamine ..........
Drug code
7437
1100
Schedule
I
II
The company plans to import drug
code 7437 (Psilocybin), as bulk and drug
code 1100 (Amphetamine), as finished
dosage form for clinical trials, research,
and analytical purposes. No other
activity for drug code 1100 is authorized
for this registration. Approval of permit
E:\FR\FM\08JYN1.SGM
08JYN1
41066
Federal Register / Vol. 85, No. 131 / Wednesday, July 8, 2020 / Notices
applications will occur only when the
registrant’s business activity is
consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization
will not extend to the import of the
Food and Drug Administrationapproved or non-approved finished
dosage forms for commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–14623 Filed 7–7–20; 8:45 am]
BILLING CODE P
MILLENNIUM CHALLENGE
CORPORATION
[MCC FR 20–03]
Renewal of the MCC Advisory Council
and Call for Nominations
Millennium Challenge
Corporation.
ACTION: Notice.
AGENCY:
In accordance with the
requirements of the Federal Advisory
Committee Act, the Millennium
Challenge Corporation (‘‘MCC’’) has
renewed the charter for the MCC
Advisory Council (‘‘Advisory Council’’)
and is hereby soliciting representative
nominations for the 2020–2022 term.
The Advisory Council serves MCC in an
advisory capacity only and provides
insight regarding (i) innovations in
relevant sectors including technology,
infrastructure and blended finance; (ii)
perceived risks and opportunities in
MCC partner countries; and (iii)
evolving approaches to working in
developing country contexts. The
Advisory Council provides a platform
for systematic engagement with the
private sector and contributes to MCC’s
mission—to reduce poverty through
sustainable, economic growth. MCC
uses this advice, information, and
recommendations to inform compact
development and implementation, and
broaden public and private sector
partnerships for more impact and
leverage. The MCC Vice President of the
Department of Compact Operations
affirms that the Advisory Council is
necessary and in the public interest. The
Advisory Council is seeking members
representing a diverse group of private
sector organizations with expertise in
infrastructure, business and finance and
technology, particularly in the countries
and regions where MCC operates.
Additional information about MCC and
its portfolio can be found at
www.mcc.gov.
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
Nominations for Advisory
Council members must be received on
DATES:
VerDate Sep<11>2014
17:17 Jul 07, 2020
Jkt 250001
or before 5 p.m. EDT on August 12,
2020. Further information about the
nomination process is included below.
MCC plans to host the first meeting of
the 2020–2022 term of the MCC
Advisory Council in Fall 2020. The
Advisory Council will meet at least two
times a year in Washington, DC or via
video/teleconferencing. Members who
are unable to attend in-person meetings
may have the option to dial-in via
video/teleconferencing.
SUPPLEMENTARY INFORMATION: The
Advisory Council shall consist of not
more than twenty-five (25) individuals
who are recognized thought leaders,
business leaders and experts
representing US companies, the
business community, advocacy
organizations, non-profit organizations,
foundations, and sectors including
infrastructure, information and
communications technology (‘‘ICT’’),
and finance, as well as the environment
and sustainable development. Qualified
individuals may self-nominate or be
nominated by any individual or
organization. To be considered for the
Advisory Council, nominators should
submit the following information:
• Name, title, organization and
relevant contact information (including
phone, mailing address, and email
address) of the individual under
consideration;
• A letter, on organization letterhead,
containing a brief description of why
the nominee should be considered for
membership;
• Short biography of nominee
including professional and academic
credentials;
Please do not send company, trade
association, or organization brochures or
any other information. Materials
submitted should total two pages or
less. Should more information be
needed, MCC staff will contact the
nominee, obtain information from the
nominee’s past affiliations, or obtain
information from publicly available
sources.
All members of the Advisory Council
will be independent of the agency,
representing the views and interests of
their respective industry or area of
expertise, and not as Special
Government employees. All members
shall serve without compensation.
Nominees selected for appointment to
the Advisory Council will be notified by
return email and receive a letter of
appointment. A selection team
comprised of representatives from
several MCC departments will review
the nomination packages. The selection
team will make recommendations
regarding membership to the MCC Vice
PO 00000
Frm 00105
Fmt 4703
Sfmt 4703
President of the Department of Compact
Operations based on criteria including:
(1) Professional or academic expertise,
experience, and knowledge; (2)
stakeholder representation; (3)
availability and willingness to serve; (4)
skills working collaboratively on
committees and advisory panels; and (5)
professional recommendations, if any
(recommendations are optional). Based
upon the selection team’s
recommendations, the MCC Vice
President of the Department of Compact
Operations will select representatives.
In the selection of members for the
Advisory Council, MCC will seek to
ensure a balanced representation and
consider a cross-section of those directly
affected, interested, and qualified, as
appropriate to the nature and functions
of the Advisory Council. Nominations
are open to all individuals without
regard to race, color, religion, sex,
gender, national origin, age, mental or
physical disability, marital status, or
sexual orientation. MCC also encourages
geographic diversity in the composition
of the Advisory Council.
FOR FURTHER INFORMATION CONTACT:
Nominators are asked to send all
nomination materials by email to
MCCAdvisoryCouncil@mcc.gov. While
email is strongly preferred, nominators
may send nomination materials by mail
to 1099 14th St NW Suite 700,
Washington, DC 20005. Requests for
additional information can also be
directed to Jennifer Rimbach,
202.521.3932, MCCAdvisoryCouncil@
mcc.gov.
Dated: July 1, 2020.
Jeanne M. Hauch,
VP/General Counsel and Corporate Secretary.
[FR Doc. 2020–14662 Filed 7–7–20; 8:45 am]
BILLING CODE 9211–03–P
NATIONAL SCIENCE FOUNDATION
Advisory Committee for Mathematical
and Physical Sciences; Notice of
Meeting
In accordance with the Federal Advisory
Committee Act (Pub. L. 92–463, as amended),
the National Science Foundation (NSF)
announces the following meeting:
Name and Committee Code: Advisory
Committee for Mathematical and
Physical Sciences (#66).
Date and Time: August 5, 2020; 12:30
p.m. to 4:45 p.m.; August 7, 2020; 12:30
p.m. to 4:30 p.m.
Place: NSF, 2415 Eisenhower Avenue,
Alexandria, VA 22314 (Virtual
attendance only).
To attend the virtual meeting, please
send your request for the virtual
E:\FR\FM\08JYN1.SGM
08JYN1
]]>Agencies
[Federal Register Volume 85, Number 131 (Wednesday, July 8, 2020)]
[Notices]
[Pages 41065-41066]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-14623]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-681]
Importer of Controlled Substances Application: Xcelience
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before August 7, 2020.
Such persons may also file a written request for a hearing on the
application on or before August 7, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on May 28, 2020, Xcelience, 4901 West Grace Street,
Tampa, Florida 33607-3805, applied to be registered as an Importer of
the following basic class(es) of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Psilocybin............................ 7437 I
Amphetamine........................... 1100 II
------------------------------------------------------------------------
The company plans to import drug code 7437 (Psilocybin), as bulk
and drug code 1100 (Amphetamine), as finished dosage form for clinical
trials, research, and analytical purposes. No other activity for drug
code 1100 is authorized for this registration. Approval of permit
[[Page 41066]]
applications will occur only when the registrant's business activity is
consistent with what is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the import of the Food and Drug
Administration-approved or non-approved finished dosage forms for
commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-14623 Filed 7-7-20; 8:45 am]
BILLING CODE P
